We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Drug Discovery Benefits from Evaporative Crystallization Technology
Product News

Drug Discovery Benefits from Evaporative Crystallization Technology

Drug Discovery Benefits from Evaporative Crystallization Technology
Product News

Drug Discovery Benefits from Evaporative Crystallization Technology


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Drug Discovery Benefits from Evaporative Crystallization Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A new technical poster produced by Genevac, in conjunction with the Novartis Institute for BioMedical Research (Horsham, UK), examines the application of eXalt™ evaporative crystallization technology to drug discovery projects.

eXalt™ is a proprietary Genevac technology designed to control evaporation using restricting baffles. Using this technology multiple solvents can be screened in parallel to identify optimum crystallization conditions for amorphous materials.

In the pharmaceutical industry, physical form can pose a significant challenge for small molecule drug discovery projects transitioning between the optimization and characterization phases. A crystalline form is desirable to confirm absolute structure as well as to investigate solubility and the formulation of a specific morphic form.

The scope of the research described in the poster was to investigate the suitability of Genevac eXalt™ evaporative crystallization technology for production of seed crystals from amorphous materials and to use these large crystals for structure determination, identification of solvates / solvation exchange, identify polymorphs and to undertake co-crystal screening.

Results from this series of projects are presented. The researchers conclude that eXalt™ technology was shown to be a versatile tool and successfully applied to novel compound classes in multiple drug discovery projects.

Further as a non-destructive technique enabling structure confirmation data to be obtained from samples as small as 5mg, eXalt™ is well suited for use in the optimization phase of early research projects.

Advertisement